Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: respiratory disease therapy - Aphoenix

Drug Profile

Research programme: respiratory disease therapy - Aphoenix

Alternative Names: AFX 002 series; AFX-300 series for respiratory disorders; Respiratory disease therapy research programme - Aphoenix

Latest Information Update: 04 Nov 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aphoenix
  • Class Small molecules
  • Mechanism of Action Chloride channel antagonists; Cytokine inhibitors; NF-kappa B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Chronic obstructive pulmonary disease; Cystic fibrosis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Chronic-obstructive-pulmonary-disease in Japan (PO)
  • 29 Jun 2005 This programme is still in active development for COPD - (BIO-2005)
  • 29 Jun 2005 No development reported - Preclinical for Cystic fibrosis in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top